Ionis Pharmaceuticals (IONS) TD Cowen 45th Annual Healthcare Conference summary

Recent drug approvals and commercial evolution

• Three drug approvals in the past 20 months, including WAINUA, QALSODY, and olezarsen, marking a transition to a fully integrated commercial-stage company.

• Olezarsen is the first FDA-approved treatment for familial chylomicronemia syndrome, with a successful launch underway.

• Four independent launches anticipated in the next few years, including donidalorsen for HAE and broader indications for olezarsen.

• Focus on continuous revenue growth and approaching profitability.

Pipeline and upcoming clinical data

• Alexander disease phase III data expected in the second half of the year, targeting GFAP with a placebo-controlled trial of about 60 patients; primary endpoint is 10-meter walk distance.

• Sapablursen phase II-A study in polycythemia vera is ongoing, with primary endpoint reduction in phlebotomy; early data show encouraging hepcidin increases and hematocrit control.

• Pelacarsen's HORIZON phase III cardiovascular outcome trial delayed to first half of 2026 due to slower event accrual; a 15%+ MACE reduction considered clinically meaningful.

• Olezarsen sHTG program includes three studies, with pivotal data from CORE and CORE2 expected in the second half of the year; focus on triglyceride lowering and acute pancreatitis risk reduction.

• Angelman syndrome phase III (ION582) to enroll broad age groups, with expressive communication as the primary endpoint; pivotal cohort is 2–17 years, with supportive adult and newborn cohorts.

Strategic focus and operational efficiencies

• Emphasis on expanding from rare to prevalent indications, including sHTG, Lp(a)-CVD, and chronic HBV.

• R&D spending expected to remain flat as older phase III studies wind down and new ones begin.

• Commercial infrastructure for rare diseases is established and will be leveraged for broader launches.

• Efficiencies in commercial operations and market access anticipated as the company shifts to more wholly owned programs.